- Previous Close
57.63 - Open
57.55 - Bid 57.31 x 100
- Ask 57.35 x 100
- Day's Range
57.18 - 57.96 - 52 Week Range
42.63 - 58.97 - Volume
1,024,771 - Avg. Volume
1,859,342 - Market Cap (intraday)
144.055B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
30.65 - EPS (TTM)
1.87 - Earnings Date Oct 25, 2024
- Forward Dividend & Yield 2.04 (3.55%)
- Ex-Dividend Date May 9, 2024
- 1y Target Est
62.29
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
www.sanofi.com86,088
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SNY
View MorePerformance Overview: SNY
Trailing total returns as of 10/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNY
View MoreValuation Measures
Market Cap
145.50B
Enterprise Value
164.44B
Trailing P/E
30.54
Forward P/E
11.61
PEG Ratio (5yr expected)
0.84
Price/Sales (ttm)
2.72
Price/Book (mrq)
1.77
Enterprise Value/Revenue
3.11
Enterprise Value/EBITDA
13.65
Financial Highlights
Profitability and Income Statement
Profit Margin
8.95%
Return on Assets (ttm)
4.16%
Return on Equity (ttm)
5.82%
Revenue (ttm)
47.08B
Net Income Avi to Common (ttm)
4.22B
Diluted EPS (ttm)
1.87
Balance Sheet and Cash Flow
Total Cash (mrq)
6.79B
Total Debt/Equity (mrq)
32.54%
Levered Free Cash Flow (ttm)
4.6B
Research Analysis: SNY
View MoreCompany Insights: SNY
SNY does not have Company Insights
Research Reports: SNY
View MoreSanofi Earnings: Strong Results Led by Dupixent, With Solid Potential Still Remaining
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
RatingPrice TargetArgus Quick Note: Weekly Stock List for 09/03/2024: Global Dividend Investing
Global stocks are gaining, if not at the pace of domestic equities. While the S&P 500 has risen 17% year to date, the EAFA index of large- and mid-cap stocks based in countries other than the U.S. and Canada has gained 9.5%. Over the past five years, the performance gap has been wider, with the S&P 500 advancing 94% compared to a 32% gain in EAFE. But the underperformance has given global stocks a valuation advantage, particularly in the area of dividends. Consider that the EAFE dividend yield of 2.9% is 170 basis points higher than the comparable S&P 500 dividend yield. We think global dividend stocks now offer opportunity, particularly given the endless speculation over the direction of interest rates in the U.S., which has created market-timing headaches for equity income investors, who have endured recent wide swings in prices for rate-sensitive equity in areas such as utilities, REITs and MLPs. In our view, investing in international income stocks is one way to increase portfolio diversification while reducing sensitivity to volatile U.S. interest rates. Investing in overseas stocks carries its own set of risks, including the impact of currency exchange and geopolitical turmoil. But there are also a number of positives in this asset class for U.S. investors, including a wide selection of companies that pay dividends, robust industry diversification, and, as we have mentioned, higher yields and lower valuations. Argus has recently boosted its global coverage, and recommends the following international dividend stocks, each of which has at least a long-term BUY rating from an Argus analyst. Note this list of approximately 25-30 companies offers exposure to eight of the 11 major industrial sectors. The list includes companies from 10 countries.
The Argus High-Yield Model Portfolio
Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022. That's a recent rarity, as for the past decade-plus, the performance record has favored growth. But in 2022, The rollout of COVID-19 vaccines gave a lift to some of the cyclical companies (energy and regional banks) that had lagged in recent quarters, and value stocks outpaced growth stocks that year. While growth stocks have retaken the lead since 2023, the Federal Reserve continues to keep interest rates high to fend off inflation. This could possibly cap multiple expansion for growth companies in coming quarters. In any event, the value sector is the place to achieve income.
Raising target to $60
Based in Paris, Sanofi focuses on treatments for diabetes and cardiovascular conditions as well as on specialty care and general medicines and consumer healthcare products. The company derives most of its revenue from the U.S., Europe, and emerging markets. It employs more than 87,000 people.
RatingPrice Target